Gammaglobulina EV (IGEV): tratamiento en inmunodeficiencias
Garip, Emilio A.
Arch. argent. alerg. inmunol. clín
; 26(2,pt.2): 158-60, 1995.
Artículo en Español | LILACS | ID: lil-166060
Documentos relacionados
Antineurofascin IgG2-associated paediatric autoimmune nodopathy.
An optimized microplate-based method to evaluate complement-dependent hemolysis mediated by intravenous immunoglobulins (IVIG).
Novel approach to monitor intravenous immunoglobulin pharmacokinetics in humans using polymorphic determinants in IgG1 constant domains.
Thawed plasma (TP) as a substitute for intravenous immune globulin (IVIG) to prevent hypogammaglobulinemia post-therapeutic plasma exchange.
Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
Evaluation of immunoglobulin replacement therapy in secondary immunodeficiency at three British Columbia hospitals.
Qualitative Immunoglobulin Deficiency Causes Bacterial Infections in Patients with STAT1 Gain-of-Function Mutations.
Relationships between bronchiectasis and time to achieving target trough immunoglobulin G levels in patients with common variable immunodeficiency.
Intravenous immunoglobulin G therapy for neonatal hyperbilirubinemia.
Adverse effects of immunoglobulin therapy.